Belpointe Asset Management LLC Reduces Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Belpointe Asset Management LLC lowered its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNFree Report) by 59.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 329 shares of the biopharmaceutical company’s stock after selling 483 shares during the quarter. Belpointe Asset Management LLC’s holdings in Regeneron Pharmaceuticals were worth $289,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of REGN. Quantbot Technologies LP purchased a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at about $90,000. Oppenheimer Asset Management Inc. lifted its position in Regeneron Pharmaceuticals by 3.0% in the third quarter. Oppenheimer Asset Management Inc. now owns 756 shares of the biopharmaceutical company’s stock valued at $622,000 after buying an additional 22 shares during the last quarter. Avantax Advisory Services Inc. lifted its position in Regeneron Pharmaceuticals by 11.1% in the third quarter. Avantax Advisory Services Inc. now owns 814 shares of the biopharmaceutical company’s stock valued at $670,000 after buying an additional 81 shares during the last quarter. Janney Montgomery Scott LLC lifted its position in Regeneron Pharmaceuticals by 7.3% in the third quarter. Janney Montgomery Scott LLC now owns 17,829 shares of the biopharmaceutical company’s stock valued at $14,672,000 after buying an additional 1,216 shares during the last quarter. Finally, Pathstone Family Office LLC lifted its position in Regeneron Pharmaceuticals by 73.0% in the third quarter. Pathstone Family Office LLC now owns 5,649 shares of the biopharmaceutical company’s stock valued at $4,682,000 after buying an additional 2,383 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Insider Transactions at Regeneron Pharmaceuticals

In other news, EVP Andrew J. Murphy sold 5,783 shares of the firm’s stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the transaction, the executive vice president now directly owns 48,306 shares in the company, valued at $46,203,239.82. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, Director Michael S. Brown sold 1,172 shares of the firm’s stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $974.86, for a total transaction of $1,142,535.92. Following the transaction, the director now directly owns 1,382 shares in the company, valued at $1,347,256.52. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Andrew J. Murphy sold 5,783 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the completion of the transaction, the executive vice president now owns 48,306 shares in the company, valued at $46,203,239.82. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 55,612 shares of company stock worth $54,346,970. Insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock opened at $1,002.95 on Friday. The firm has a market capitalization of $110.52 billion, a P/E ratio of 29.63, a P/E/G ratio of 2.07 and a beta of 0.13. Regeneron Pharmaceuticals, Inc. has a 52 week low of $684.80 and a 52 week high of $1,016.00. The company has a quick ratio of 4.51, a current ratio of 5.27 and a debt-to-equity ratio of 0.10. The firm’s 50 day moving average is $949.32 and its two-hundred day moving average is $927.00.

Regeneron Pharmaceuticals (NASDAQ:REGNGet Free Report) last announced its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 EPS for the quarter, missing the consensus estimate of $8.46 by ($0.49). The company had revenue of $3.15 billion during the quarter, compared to analysts’ expectations of $3.19 billion. Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.23 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. TD Cowen upped their target price on shares of Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the company a “buy” rating in a research report on Wednesday, April 24th. Sanford C. Bernstein assumed coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 target price on the stock. Truist Financial reaffirmed a “buy” rating and issued a $1,135.00 target price on shares of Regeneron Pharmaceuticals in a research report on Wednesday, April 3rd. StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, April 30th. Finally, Royal Bank of Canada increased their price target on shares of Regeneron Pharmaceuticals from $1,185.00 to $1,200.00 and gave the stock an “outperform” rating in a research report on Tuesday. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $989.86.

Check Out Our Latest Stock Analysis on Regeneron Pharmaceuticals

About Regeneron Pharmaceuticals

(Free Report)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Further Reading

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.